Clinical Study of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Treatment of Patients with Advanced Non-Small-cell Lung Cancer

林蓉燕,赵玉亮,于晶琳,白羽,方红,孙明霞,徐玲

DOI: https://doi.org/10.3969/j.issn.1005-8664.2004.05.009

2004-01-01

Abstract:Objective To compare the efficacy and toxicity of vinorelbine plus cisplatin(NP) and paclita-xel plus cisplatin(TP) combinations in the treatment of advanced non-small-cell lung cancer(NSCLC) .Methods From December 1997 to April 2002, a total of 59 patients with advanced NSCLC were randomized to receive vinorelbine 25 mg/m2 on days 1,8 by twenty-minute infusion and cisplatin 45 mg/m2 on day 1 (group NP) , or paclita-xel 135 mg/m2 by 3-hour infusion and cisplatin 80 mg/m2 on day 1(group TP). Both regimens were repeated every 3 weeks. Results A total of 59 patients (30 patients in group TP, 29 patients in group TP) were enrolled. All characteristics were well matched between the two groups. In total, 188 cycles of NP and 93 cycles of TP were given. The median duration of response was 5.5 months for group NP and 4.5 months for group TP.The overall response rate for group NP was 46.7% , with 6.6% complete response(CR) ,40.0% partial response(PR) ,40.0% stable disease(SD) and 13. 3% progression of disease(PD), and in group TP, the overall response rate was 44. 8% (3.4% CR,41.4% PR,37.9% SD,and 17.2% PD)(P0.75).The response rate was higher in grade Ⅲb cases than in grade Ⅳ cases(77.8% vs 33.3% in group NP,P = 0.0288,and 85.7% vs 31.8% in group TP, P = 0.0176),higher in previously untreated cases than in treated cases(72.7% vs 31.6% in group NP, P = 0.0308,and 75.0% vs 33.3% in group TP, P = 0.0480).The incidence of neutropenia and thrombocytopenia were 66.7% and 51.7% in group NP,and 33.3% and 31.0% in group TP,respectively.Phlebitis(63.3% vs 3.4%)and nausea/vomiting(55.3% vs 41.4%)were more severe in group NP.By contrast,alopecia(93.1% vs 23.3%)and peripheral neurotoxicity/myalgia(72.4% vs 36.7%)were more frequent in group TP.The frequency and severity of other toxic reactions were comparable between the two groups. No WHO grade Ⅳ toxicity occurred. Conclusion Both NP and TP combined chemotherapy produce similar efficacy and are well tolerated in patients with advanced non-small-cell lung cancer.